The latest announcement is out from Noxopharm Ltd. ( (AU:NOX) ).
Noxopharm Limited reported its financial results for the half-year ending December 2024, highlighting a cash balance of $1.0 million and an investment of $1.6 million in R&D to advance drug discovery. The company is preparing for the HERACLES clinical trial for its lupus drug candidate, SOF-SKN™, and is pursuing Material Transfer Agreements to leverage interest in its Sofra™ technology platform. These efforts reflect Noxopharm’s strategic focus on cost management and advancing its drug development pipeline, which could impact its market positioning and stakeholder interests.
More about Noxopharm Ltd.
Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company utilizes in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on its Chroma™ and Sofra™ technology platforms. Noxopharm also holds a major shareholding in Nyrada Inc, a company specializing in novel small molecule therapies.
YTD Price Performance: -12.90%
Average Trading Volume: 108,164
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$23.67M
See more data about NOX stock on TipRanks’ Stock Analysis page.